Clinical Trials Logo

Breast Adenocarcinoma clinical trials

View clinical trials related to Breast Adenocarcinoma.

Filter by:

NCT ID: NCT06401889 Not yet recruiting - Clinical trials for Anatomic Stage III Breast Cancer AJCC v8

Enhancing Skin Appearance and Quality of Life in Breast Cancer Survivors on Aromatase Inhibitor Therapy

Start date: June 1, 2024
Phase:
Study type: Observational

This study evaluates changes in skin quality and self-esteem among breast cancer patients who are initiating aromatase inhibitor therapy.

NCT ID: NCT06234488 Active, not recruiting - Breast Cancer Clinical Trials

Multi-Institutional Transgender & Gender-Diverse Breast Cancer Study

Start date: December 8, 2023
Phase:
Study type: Observational

There is no granular retrospective data on breast cancer in transgender and gender-diverse (TGD) persons from a contemporary and diverse American cohort. The purpose of this investigation is to aggregate data from multiple institutions to describe the risk, diagnosis, management, and outcomes of TGD persons with breast cancer in effort to identify opportunities for future intervention studies to eliminate breast cancer disparities for this population.

NCT ID: NCT05579366 Recruiting - Ovarian Cancer Clinical Trials

PRO1184 for Advanced Solid Tumors

PRO1184-001
Start date: December 7, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This study will test the safety, including side effects, and determine the characteristics of a drug called PRO1184 in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable).

NCT ID: NCT05447910 Recruiting - Clinical trials for Invasive Breast Carcinoma

Analysis of Letrozole in Patients With Operable Hormone Receptor Positive, HER2 Negative Breast Cancer

Start date: July 21, 2022
Phase: Phase 2
Study type: Interventional

This phase II trial examines letrozole in patients with newly diagnosed hormone receptor-positive HER2-negative invasive breast cancer that can be removed by surgery (operable). Letrozole is in a class of medications called nonsteroidal aromatase inhibitors. It works by decreasing the amount of estrogen produced by the body. This can slow or stop the growth of some types of breast cancer cells that need estrogen to grow.

NCT ID: NCT05183828 Recruiting - Clinical trials for Anatomic Stage III Breast Cancer AJCC v8

Effect of HSD3B1 (1245C) Gene Mutation on Treatment of Stage I-III Breast Cancer

Start date: January 23, 2022
Phase: Phase 4
Study type: Interventional

This stage IV trial examines how a mutation in HSD3B1 (1245C) gene affects treatment of stage I-III breast cancer. This trial may help researchers determine if mutations in HSD3B1 decreases the efficacy of aromatase inhibitor therapy such as letrozole. Letrozole may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT04857697 Completed - Clinical trials for Anatomic Stage III Breast Cancer AJCC v8

Effects of Probiotics on the Gut Microbiome and Immune System in Operable Stage I-III Breast or Lung Cancer

Start date: July 1, 2021
Phase: Early Phase 1
Study type: Interventional

This clinical trial evaluates whether engineering gut microbiome using probiotics will alter the body's immune system to react to stage I-III breast or lung cancers that can be removed by surgery (operable). Having diverse species of bacteria inside the bowel may help improve the immune system, particularly the ability of the immune system to recognize cancer. Taking probiotics may change the diversity and make up of the bacteria in the bowels, and change how the immune system reacts to breast or lung cancer.

NCT ID: NCT04769960 Active, not recruiting - Breast Cancer Clinical Trials

Study of the Safety of MRI Scans in People Who Have Breast Tissue Expanders After Mastectomy

Start date: February 19, 2021
Phase:
Study type: Observational

The purpose of this study is to find out whether it is safe to perform MRI scans in people who have breast tissue expanders in place.

NCT ID: NCT04535323 Completed - Clinical trials for Anatomic Stage III Breast Cancer AJCC v8

Platelet Rich Plasma for the Treatment of Genitourinary Syndrome of Menopause in Patients With Stage 0-III Breast Cancer

Start date: September 23, 2020
Phase: Phase 1
Study type: Interventional

This phase I trial is to find out possible benefits and/or side effects of platelet rich plasma for the treatment of genitourinary syndrome of menopause in patients with stage 0-III breast cancer. Platelet rich plasma is produced by collecting approximately 60-90 ml (4-6 tablespoons) of blood from the vein in patients' arm. The blood is spun using a centrifuge that separates the plasma and red blood cells. This allows doctors to collect the platelet rich plasma that is then loaded into individual, sterile syringes for injection. Giving platelet rich plasma may help relief symptoms of genitourinary syndrome of menopause in patients with breast cancer.

NCT ID: NCT04517838 Recruiting - Clinical trials for Breast Adenocarcinoma

Immune Response to Anti-HER2 Therapies in Patients With HER2-Positive Stage I-IV Breast Cancer

Start date: July 27, 2020
Phase:
Study type: Observational

This study gathers information from the blood cells and tumor tissue during treatment with anti-HER2 therapies, such as trastuzumab, pertuzumab, lapatinib, or neratinib, in patients with HER2 positive stage I-IV breast cancer who are scheduled to start anti-HER2 therapy. The information gained from this study may help researchers better understand the relation between cell response and anti-HER2 therapies.

NCT ID: NCT04300829 Recruiting - Radiation Toxicity Clinical Trials

Cicaderma Efficacy vs Standard Care of Sites in Preventing Radiodermatitis in Non-metastatic Breast Cancer Patients

CICA-RT
Start date: June 6, 2020
Phase: Phase 3
Study type: Interventional

Phase III, prospective, interventional, multicentric, comparative, randomized, open study with 2 parallel arms, evaluating the efficacy of Cicaderma ointment vs standard management of each site in preventing the onset of grade > 2 radiodermatitis according to the National Cancer Institute - Common Terminology Criteria for Adverse Events-Version (NCI-CTCAE-V5)